Venrock Adviser, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Venrock Adviser, LLC reported 38 stock positions worth $2.1 billion. Its top holding was Apogee Therapeutics (APGE) at 26.8% of the portfolio, followed by 4D Molecular Therapeutics (FDMT, 6.7%) and Ocular Therapeutix (OCUL, 5.5%). Compared with Q4 2023, it opened 9 new positions, sold out of 7, added to 14 and reduced 6. The biggest buy was Ocular Therapeutix (OCUL, shares +64%) and the biggest sale an exit from Rayzebio (RYZB).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001615982
- Portfolio Value
- $2.1B (Q1 2024)
- SEC Filing
- 0001104659-24-061948 ↗ filed May 15, 2024
Holdings Value
Holdings 38 stocks · $2.1B
| APGE Apogee Therapeutics Inc. | 26.85% | 8,493,321 | $564.4M | No change |
| FDMT 4D Molecular Therapeutics Inc. | 6.67% | 4,400,000 | $140.2M | Add +28.5% |
| OCUL Ocular Therapeutix Inc. | 5.52% | 12,762,462 | $116.1M | Add +64.1% |
| SYRE Spyre Therapeutics Inc. | 3.92% | 2,171,782 | $82.4M | Reduce -8.5% |
| MRUS Merus NV | 3.83% | 1,790,214 | $80.6M | Reduce -16.7% |
| PHVS Pharvaris NV | 3.73% | 3,395,606 | $78.5M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 3.53% | 6,249,731 | $74.1M | Add +52.7% |
| ELVN Enliven Therapeutics Inc. | 3.37% | 4,026,331 | $70.8M | Add +36.3% |
| VRDN Viridian Therapeutics Inc. | 3.23% | 3,882,671 | $68.0M | Add +0.0% |
| DNTH Dianthus Therapeutics Inc. | 2.99% | 2,094,373 | $62.8M | Add +125.8% |
| DYN Dyne Therapeutics Inc. | 2.94% | 2,173,913 | $61.7M | No change |
| APLT Applied Therapeutics Inc. | 2.94% | 9,075,000 | $61.7M | Add +45.2% |
| ORIC Oric Pharmaceuticals Inc. | 2.87% | 4,394,527 | $60.4M | Add +81.0% |
| ATXS Astria Therapeutics Inc. | 2.42% | 3,608,645 | $50.8M | Add +11.9% |
| MERSANA THERAPEUTICS INC | 2.41% | 11,328,000 | $50.7M | No change |
| ENGN Engene Holdings Inc. | 2.07% | 2,565,841 | $43.5M | New |
| PRAX Praxis Precision Medicines I | 2.05% | 706,126 | $43.1M | Add +99.7% |
| HLVX Hillevax Inc. | 1.64% | 2,075,000 | $34.5M | No change |
| COGT Cogent Biosciences Inc. | 1.64% | 5,129,167 | $34.5M | Add +9.5% |
| EWTX Edgewise Therapeutics Inc. | 1.58% | 1,818,182 | $33.2M | New |
| CABA Cabaletta Bio Inc. | 1.27% | 1,563,952 | $26.7M | Reduce -39.0% |
| ARVN Arvinas Inc. | 1.23% | 627,788 | $25.9M | No change |
| TSHA Taysha Gene Therapies Inc. | 1.23% | 9,000,000 | $25.8M | Reduce -13.6% |
| AQST Aquestive Therapeutics Inc. | 1.13% | 5,555,555 | $23.7M | New |
| TERN Terns Pharmaceuticals Inc. | 1.06% | 3,410,058 | $22.4M | Reduce -24.2% |
| ADVM Adverum Biotechnologies Inc. | 1.05% | 1,556,419 | $22.0M | New |
| CELC Celcuity Inc. | 1.00% | 970,000 | $21.0M | Reduce -48.6% |
| ABVX Abivax SA-ADR | 0.92% | 1,345,780 | $19.2M | Add +34.8% |
| IMTX Immatics NV | 0.87% | 1,750,000 | $18.4M | New |
| LYRA Lyra Therapeutics Inc. | 0.76% | 2,576,093 | $16.0M | Add +0.0% |
| CGON CG Oncology Inc. | 0.73% | 350,000 | $15.4M | New |
| IPSC Century Therapeutics Inc. | 0.68% | 3,405,133 | $14.2M | New |
| TRVI Trevi Therapeutics Inc. | 0.56% | 3,422,675 | $11.8M | Add +0.0% |
| TNYA Tenaya Therapeutics Inc. | 0.39% | 1,555,556 | $8.1M | New |
| MLYS Mineralys Therapeutics Inc. | 0.34% | 555,554 | $7.2M | New |
| SLRN Acelyrin Inc. | 0.30% | 937,113 | $6.3M | No change |
| EYPT Eyepoint Inc. | 0.25% | 250,000 | $5.2M | No change |
| OLMA Olema Pharmaceuticals Inc. | 0.04% | 77,042 | $872K | No change |
Portfolio Sells Q4 2023 → Q1 2024
| RYZB Rayzebio Inc. | Sold out | 0.00% | −17.19 |
| CABA Cabaletta Bio Inc. | Reduce -39.0% | 1.27% | −2.72 |
| AMAM New Ambrx Biopharma Inc. | Sold out | 0.00% | −2.02 |
| RYTM Rhythm Pharmaceuticals Inc. | Sold out | 0.00% | −1.56 |
| SVRA Savara Inc. | Sold out | 0.00% | −1.13 |
| TERN Terns Pharmaceuticals Inc. | Reduce -24.2% | 1.06% | −0.94 |
| CELC Celcuity Inc. | Reduce -48.6% | 1.00% | −0.89 |
| GHRS GH Research PLC | Sold out | 0.00% | −0.52 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.27 |
| MRUS Merus NV | Reduce -16.7% | 3.83% | −0.22 |
| MIST Milestone Pharmaceuticals Inc. | Sold out | 0.00% | −0.11 |
| TSHA Taysha Gene Therapies Inc. | Reduce -13.6% | 1.23% | −0.04 |
| SYRE Spyre Therapeutics Inc. | Reduce -8.5% | 3.92% | +0.42 |
Portfolio Buys Q4 2023 → Q1 2024
| OCUL Ocular Therapeutix Inc. | Add +64.1% | 5.52% | +3.15 |
| DNTH Dianthus Therapeutics Inc. | Add +125.8% | 2.99% | +2.33 |
| ENGN Engene Holdings Inc. | New | 2.07% | +2.07 |
| FDMT 4D Molecular Therapeutics Inc. | Add +28.5% | 6.67% | +1.91 |
| EWTX Edgewise Therapeutics Inc. | New | 1.58% | +1.58 |
| PRAX Praxis Precision Medicines I | Add +99.7% | 2.05% | +1.51 |
| APLT Applied Therapeutics Inc. | Add +45.2% | 2.94% | +1.50 |
| ORIC Oric Pharmaceuticals Inc. | Add +81.0% | 2.87% | +1.34 |
| AQST Aquestive Therapeutics Inc. | New | 1.13% | +1.13 |
| ADVM Adverum Biotechnologies Inc. | New | 1.05% | +1.05 |
| IMTX Immatics NV | New | 0.87% | +0.87 |
| CGON CG Oncology Inc. | New | 0.73% | +0.73 |
| ATXS Astria Therapeutics Inc. | Add +11.9% | 2.42% | +0.72 |
| IPSC Century Therapeutics Inc. | New | 0.68% | +0.68 |
| ELVN Enliven Therapeutics Inc. | Add +36.3% | 3.37% | +0.56 |
| TNYA Tenaya Therapeutics Inc. | New | 0.39% | +0.39 |
| MLYS Mineralys Therapeutics Inc. | New | 0.34% | +0.34 |
| TRVI Trevi Therapeutics Inc. | Add +0.0% | 0.56% | +0.25 |
| ABVX Abivax SA-ADR | Add +34.8% | 0.92% | +0.18 |
| KALV Kalvista Pharmaceuticals Inc. | Add +52.7% | 3.53% | +0.09 |
| LYRA Lyra Therapeutics Inc. | Add +0.0% | 0.76% | −0.16 |
| COGT Cogent Biosciences Inc. | Add +9.5% | 1.64% | −0.25 |
| VRDN Viridian Therapeutics Inc. | Add +0.0% | 3.23% | −2.57 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $3.3B | APGE, ORKA, ERAS, SYRE, DNTH |
| Q1 2026 | 33 | $2.7B | APGE, ERAS, ORKA, SYRE, KALV |
| Q4 2025 | 27 | $2.0B | APGE, ORKA, VRDN, SYRE, KALV |
| Q3 2025 | 33 | $1.8B | APGE, MTSR, OCUL, CDTX, VRDN |
| Q2 2025 | 31 | $1.3B | APGE, OCUL, MTSR, ELVN, KALV |
| Q1 2025 | 37 | $1.2B | APGE, MTSR, OCUL, ELVN, KALV |
| Q4 2024 | 37 | $1.5B | APGE, OCUL, ELVN, PRAX, VRDN |
| Q3 2024 | 38 | $1.9B | APGE, OCUL, ELVN, VRDN, APLT |
| Q2 2024 | 35 | $1.6B | APGE, ELVN, FDMT, OCUL, DYN |
| Q1 2024 | 38 | $2.1B | APGE, FDMT, OCUL, SYRE, MRUS |